Advertisement

The clinical role of circulating free tumor DNA in gastrointestinal malignancy

Published:December 22, 2016DOI:https://doi.org/10.1016/j.trsl.2016.12.006
      Circulating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells into the bloodstream. While both healthy cells and cancer cells release cfDNA, tumors are associated with higher levels of tumor-derived circulating cell-free DNA (ctDNA) detectable in blood. Absolute levels of ctDNA and its genetic mutations and epigenetic changes show promise as potentially useful biomarkers of tumor biology, progression, and response to therapy. Moreover, studies have demonstrated the discriminative accuracy of ctDNA levels for diagnosis of gastrointestinal cancer compared with benign inflammatory diseases. Therefore, ctDNA detected in blood offers a minimally invasive and easily repeated “liquid biopsy” of cancer, facilitating real-time dynamic analysis of tumor behavior that could revolutionize both clinical and research practices in oncology. In this review, we provide a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in gastrointestinal malignancies.

      Abbreviations:

      cfDNA (circulating cell-free DNA), ctDNA (circulating cell-free tumor-derived DNA), NGS (next generation sequencing), ALU (short interspersed nucleic acid element repeats), LINE1 (long interspersed nucleotide elements), RT-PCR (reverse transcriptase polymerase chain reaction), CRC (colorectal cancer), GIST (gastrointestinal stromal tumor), HCC (hepatocellular carcinoma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lecomte T.
        • Ceze N.
        • Dorval E.
        • Laurent-Puig P.
        Circulating free tumor DNA and colorectal cancer.
        Gastroenterol Clin Biol. 2010; 34: 662-681
        • Alix-Panabieres C.
        • Schwarzenbach H.
        • Pantel K.
        Circulating tumor cells and circulating tumor DNA.
        Annu Rev Med. 2012; 63: 199-215
        • Shapiro B.
        • Chakrabarty M.
        • Cohn E.M.
        • Leon S.A.
        Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease.
        Cancer. 1983; 51: 2116-2120
        • Alix-Panabieres C.
        • Pantel K.
        Circulating tumor cells: liquid biopsy of cancer.
        Clin Chem. 2013; 59: 110-118
        • Heitzer E.
        • Ulz P.
        • Geigl J.B.
        Circulating tumor DNA as a liquid biopsy for cancer.
        Clin Chem. 2015; 61: 112-123
        • Bettegowda C.
        • Sausen M.
        • Leary R.J.
        • et al.
        Detection of circulating tumor DNA in early- and late-stage human malignancies.
        Sci Transl Med. 2014; 6: 224ra24
        • Schwarzenbach H.
        • Hoon D.S.
        • Pantel K.
        Cell-free nucleic acids as biomarkers in cancer patients.
        Nat Rev Cancer. 2011; 11: 426-437
        • Mouliere F.
        • El Messaoudi S.
        • Pang D.
        • Dritschilo A.
        • Thierry A.R.
        Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.
        Mol Oncol. 2014; 8: 927-941
        • Boynton K.A.
        • Summerhayes I.C.
        • Ahlquist D.A.
        • Shuber A.P.
        DNA integrity as a potential marker for stool-based detection of colorectal cancer.
        Clin Chem. 2003; 49: 1058-1065
        • Lo Y.M.
        • Zhang J.
        • Leung T.N.
        • Lau T.K.
        • Chang A.M.
        • Hjelm N.M.
        Rapid clearance of fetal DNA from maternal plasma.
        Am J Hum Genet. 1999; 64: 218-224
        • Tsumita T.
        • Iwanaga M.
        Fate of injected deoxyribonucleic acid in mice.
        Nature. 1963; 198: 1088-1089
        • Leary R.J.
        • Sausen M.
        • Kinde I.
        • et al.
        Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.
        Sci Transl Med. 2012; 4: 162ra54
        • Jiang N.
        • Pisetsky D.S.
        The effect of inflammation on the generation of plasma DNA from dead and dying cells in the peritoneum.
        J Leukoc Biol. 2005; 77: 296-302
        • Lo Y.M.
        • Rainer T.H.
        • Chan L.Y.
        • Hjelm N.M.
        • Cocks R.A.
        Plasma DNA as a prognostic marker in trauma patients.
        Clin Chem. 2000; 46: 319-323
        • Maire F.
        • Micard S.
        • Hammel P.
        • et al.
        Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
        Br J Cancer. 2002; 87: 551-554
        • Salbe C.
        • Trevisiol C.
        • Ferruzzi E.
        • et al.
        Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients.
        Int J Biol Markers. 2000; 15: 300-307
        • Lee B.B.
        • Lee E.J.
        • Jung E.H.
        • et al.
        Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer.
        Clin Cancer Res. 2009; 15: 6185-6191
        • Heitzer E.
        • Auer M.
        • Ulz P.
        • Geigl J.B.
        • Speicher M.R.
        Circulating tumor cells and DNA as liquid biopsies.
        Genome Med. 2013; 5: 73
        • Haber D.A.
        • Velculescu V.E.
        Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
        Cancer Discov. 2014; 4: 650-661
        • Leary R.J.
        • Kinde I.
        • Diehl F.
        • et al.
        Development of personalized tumor biomarkers using massively parallel sequencing.
        Sci Transl Med. 2010; 2: 20ra14
        • Luke J.J.
        • Oxnard G.R.
        • Paweletz C.P.
        • et al.
        Realizing the potential of plasma genotyping in an age of genotype-directed therapies.
        J Natl Cancer Inst. 2014; 106
        • Diehl F.
        • Schmidt K.
        • Choti M.A.
        • et al.
        Circulating mutant DNA to assess tumor dynamics.
        Nat Med. 2008; 14: 985-990
        • da Silva Filho B.F.
        • Gurgel A.P.
        • Neto M.A.
        • et al.
        Circulating cell-free DNA in serum as a biomarker of colorectal cancer.
        J Clin Pathol. 2013; 66: 775-778
        • Tangkijvanich P.
        • Hourpai N.
        • Rattanatanyong P.
        • Wisedopas N.
        • Mahachai V.
        • Mutirangura A.
        Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma.
        Clin Chim Acta. 2007; 379: 127-133
        • Umetani N.
        • Kim J.
        • Hiramatsu S.
        • et al.
        Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.
        Clin Chem. 2006; 52: 1062-1069
        • Fu X.
        • Wan S.
        • Hann H.W.
        • et al.
        Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection.
        Eur J Cancer. 2012; 48: 1014-1022
        • Robertson K.D.
        DNA methylation and human disease.
        Nat Rev Genet. 2005; 6: 597-610
        • Li L.
        • Choi J.Y.
        • Lee K.M.
        • et al.
        DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology.
        J Epidemiol. 2012; 22: 384-394
        • Wilson A.S.
        • Power B.E.
        • Molloy P.L.
        DNA hypomethylation and human diseases.
        Biochim Biophys Acta. 2007; 1775: 138-162
        • Zhang Y.J.
        • Wu H.C.
        • Shen J.
        • et al.
        Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.
        Clin Cancer Res. 2007; 13: 2378-2384
        • Markowitz S.D.
        • Bertagnolli M.M.
        Molecular origins of cancer: molecular basis of colorectal cancer.
        N Engl J Med. 2009; 361: 2449-2460
        • Schwarzenbach H.
        • Stoehlmacher J.
        • Pantel K.
        • Goekkurt E.
        Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.
        Ann N Y Acad Sci. 2008; 1137: 190-196
        • Boni L.
        • Cassinotti E.
        • Canziani M.
        • Dionigi G.
        • Rovera F.
        • Dionigi R.
        Free circulating DNA as possible tumour marker in colorectal cancer.
        Surg Oncol. 2007; 16 Suppl 1: S29-S31
        • Frattini M.
        • Gallino G.
        • Signoroni S.
        • et al.
        Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool.
        Ann N Y Acad Sci. 2006; 1075: 185-190
        • Frattini M.
        • Gallino G.
        • Signoroni S.
        • et al.
        Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer.
        Cancer Lett. 2008; 263: 170-181
        • Teschendorff A.E.
        • Menon U.
        • Gentry-Maharaj A.
        • et al.
        Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer.
        Genome Res. 2010; 20: 440-446
        • Flamini E.
        • Mercatali L.
        • Nanni O.
        • et al.
        Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
        Clin Cancer Res. 2006; 12: 6985-6988
        • Lin J.K.
        • Lin P.C.
        • Lin C.H.
        • et al.
        Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
        Ann Surg Oncol. 2014; 21 Suppl 4: S680-S686
        • Wallner M.
        • Herbst A.
        • Behrens A.
        • et al.
        Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
        Clin Cancer Res. 2006; 12: 7347-7352
        • Tabernero J.
        • Lenz H.J.
        • Siena S.
        • et al.
        Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
        Lancet Oncol. 2015; 16: 937-948
        • Danese E.
        • Montagnana M.
        • Minicozzi A.M.
        • et al.
        Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers.
        Clin Chem Lab Med. 2010; 48: 1665-1668
        • Perrone F.
        • Lampis A.
        • Bertan C.
        • et al.
        Circulating free DNA in a screening program for early colorectal cancer detection.
        Tumori. 2014; 100: 115-121
        • Zitt M.
        • Muller H.M.
        • Rochel M.
        • et al.
        Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring.
        Dis Markers. 2008; 25: 159-165
        • Andreyev H.J.
        • Norman A.R.
        • Cunningham D.
        • et al.
        Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study.
        Br J Cancer. 2001; 85: 692-696
        • Thierry A.R.
        • Mouliere F.
        • El Messaoudi S.
        • et al.
        Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
        Nat Med. 2014; 20: 430-435
        • Roperch J.P.
        • Incitti R.
        • Forbin S.
        • et al.
        Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
        BMC Cancer. 2013; 13: 566
        • Breitling L.P.
        • Yang R.
        • Korn B.
        • Burwinkel B.
        • Brenner H.
        Tobacco-smoking-related differential DNA methylation: 27K discovery and replication.
        Am J Hum Genet. 2011; 88: 450-457
        • Zhang F.F.
        • Cardarelli R.
        • Carroll J.
        • et al.
        Physical activity and global genomic DNA methylation in a cancer-free population.
        Epigenetics. 2011; 6: 293-299
        • Kuo Y.B.
        • Chen J.S.
        • Fan C.W.
        • Li Y.S.
        • Chan E.C.
        Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
        Clin Chim Acta. 2014; 433: 284-289
        • Taly V.
        • Pekin D.
        • Benhaim L.
        • et al.
        Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
        Clin Chem. 2013; 59: 1722-1731
        • Span M.
        • Moerkerk P.T.
        • De Goeij A.F.
        • Arends J.W.
        A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients.
        Int J Cancer. 1996; 69: 241-245
        • Taback B.
        • Saha S.
        • Hoon D.S.
        Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients.
        Ann N Y Acad Sci. 2006; 1075: 197-203
        • Spindler K.L.
        • Pallisgaard N.
        • Andersen R.F.
        • Jakobsen A.
        Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
        Int J Cancer. 2014; 135: 2215-2222
        • Zitt M.
        • Zitt M.
        • Muller H.M.
        DNA methylation in colorectal cancer–impact on screening and therapy monitoring modalities?.
        Dis Markers. 2007; 23: 51-71
        • Holdenrieder S.
        • Dharuman Y.
        • Standop J.
        • et al.
        Novel serum nucleosomics biomarkers for the detection of colorectal cancer.
        Anticancer Res. 2014; 34: 2357-2362
        • Toth K.
        • Sipos F.
        • Kalmar A.
        • et al.
        Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.
        PLoS One. 2012; 7: e46000
        • deVos T.
        • Tetzner R.
        • Model F.
        • et al.
        Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
        Clin Chem. 2009; 55: 1337-1346
        • Grutzmann R.
        • Molnar B.
        • Pilarsky C.
        • et al.
        Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay.
        PLoS One. 2008; 3: e3759
        • Lofton-Day C.
        • Model F.
        • Devos T.
        • et al.
        DNA methylation biomarkers for blood-based colorectal cancer screening.
        Clin Chem. 2008; 54: 414-423
        • Boland C.R.
        • Goel A.
        Somatic evolution of cancer cells.
        Semin Cancer Biol. 2005; 15: 436-450
        • Beroud C.
        • Soussi T.
        APC gene: database of germline and somatic mutations in human tumors and cell lines.
        Nucleic Acids Res. 1996; 24: 121-124
        • Diehl F.
        • Li M.
        • Dressman D.
        • et al.
        Detection and quantification of mutations in the plasma of patients with colorectal tumors.
        Proc Natl Acad Sci U S A. 2005; 102: 16368-16373
        • Baker S.J.
        • Preisinger A.C.
        • Jessup J.M.
        • et al.
        p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
        Cancer Res. 1990; 50: 7717-7722
        • Borchers R.
        • Heinzlmann M.
        • Zahn R.
        • et al.
        K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease.
        Scand J Gastroenterol. 2002; 37: 715-718
        • Zhang F.F.
        • Morabia A.
        • Carroll J.
        • et al.
        Dietary patterns are associated with levels of global genomic DNA methylation in a cancer-free population.
        J Nutr. 2011; 141: 1165-1171
        • Fearon E.R.
        • Vogelstein B.
        A genetic model for colorectal tumorigenesis.
        Cell. 1990; 61: 759-767
        • Jubb A.M.
        • Bell S.M.
        • Quirke P.
        Methylation and colorectal cancer.
        J Pathol. 2001; 195: 111-134
        • Reinert T.
        • Scholer L.V.
        • Thomsen R.
        • et al.
        Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.
        Gut. 2016; 65: 625-634
        • Kim J.W.
        • Park H.M.
        • Choi Y.K.
        • Chong S.Y.
        • Oh D.
        • Kim N.K.
        Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients.
        Oncol Rep. 2011; 25: 167-172
        • Hibi K.
        • Mizukami H.
        • Saito M.
        • Kigawa G.
        • Nemoto H.
        p16 Methylation is frequently detected in the serum of metastatic colorectal cancer patients.
        Hepatogastroenterology. 2014; 61: 354-356
        • Ladabaum U.
        • Allen J.
        • Wandell M.
        • Ramsey S.
        Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 1567-1576
        • Wang Y.C.
        • Yu Z.H.
        • Liu C.
        • et al.
        Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
        World J Gastroenterol. 2008; 14: 3074-3080
        • Tham C.
        • Chew M.
        • Soong R.
        • et al.
        Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
        Cancer. 2014; 120: 3131-3141
        • Leung W.K.
        • To K.F.
        • Man E.P.
        • et al.
        Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer.
        Am J Gastroenterol. 2005; 100: 2274-2279
        • Philipp A.B.
        • Stieber P.
        • Nagel D.
        • et al.
        Prognostic role of methylated free circulating DNA in colorectal cancer.
        Int J Cancer. 2012; 131: 2308-2319
        • Herbst A.
        • Rahmig K.
        • Stieber P.
        • et al.
        Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer.
        Am J Gastroenterol. 2011; 106: 1110-1118
        • Ryan B.M.
        • Lefort F.
        • McManus R.
        • et al.
        A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.
        Gut. 2003; 52: 101-108
        • Mead R.
        • Duku M.
        • Bhandari P.
        • Cree I.A.
        Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.
        Br J Cancer. 2011; 105: 239-245
        • Hao T.B.
        • Shi W.
        • Shen X.J.
        • et al.
        Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.
        Br J Cancer. 2014; 111: 1482-1489
        • Bos J.L.
        • Fearon E.R.
        • Hamilton S.R.
        • et al.
        Prevalence of ras gene mutations in human colorectal cancers.
        Nature. 1987; 327: 293-297
        • Vogelstein B.
        • Fearon E.R.
        • Hamilton S.R.
        • et al.
        Genetic alterations during colorectal-tumor development.
        N Engl J Med. 1988; 319: 525-532
        • Lecomte T.
        • Berger A.
        • Zinzindohoue F.
        • et al.
        Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
        Int J Cancer. 2002; 100: 542-548
        • Kopreski M.S.
        • Benko F.A.
        • Borys D.J.
        • Khan A.
        • McGarrity T.J.
        • Gocke C.D.
        Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.
        J Natl Cancer Inst. 2000; 92: 918-923
        • Ito T.
        • Kaneko K.
        • Makino R.
        • et al.
        Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma.
        Oncol Rep. 2003; 10: 1937-1942
        • Lilleberg S.L.
        • Durocher J.
        • Sanders C.
        • Walters K.
        • Culver K.
        High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
        Ann N Y Acad Sci. 2004; 1022: 250-256
        • Jin P.
        • Kang Q.
        • Wang X.
        • et al.
        Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
        J Gastroenterol Hepatol. 2015; 30: 830-833
        • Toth K.
        • Wasserkort R.
        • Sipos F.
        • et al.
        Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA.
        PLoS One. 2014; 9: e115415
        • Church T.R.
        • Wandell M.
        • Lofton-Day C.
        • et al.
        Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
        Gut. 2014; 63: 317-325
        • Ahlquist D.A.
        • Taylor W.R.
        • Mahoney D.W.
        • et al.
        The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
        Clin Gastroenterol Hepatol. 2012; 10: 272-277. e1
        • Grady W.M.
        • Rajput A.
        • Lutterbaugh J.D.
        • Markowitz S.D.
        Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.
        Cancer Res. 2001; 61: 900-902
        • Lefebure B.
        • Charbonnier F.
        • Di Fiore F.
        • et al.
        Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer.
        Ann Surg. 2010; 251: 275-280
        • Kolble K.
        • Ullrich O.M.
        • Pidde H.
        • et al.
        Microsatellite alterations in serum DNA of patients with colorectal cancer.
        Lab Invest. 1999; 79: 1145-1150
        • Czeiger D.
        • Shaked G.
        • Eini H.
        • et al.
        Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer.
        Am J Clin Pathol. 2011; 135: 264-270
        • Lindforss U.
        • Zetterquist H.
        • Papadogiannakis N.
        • Olivecrona H.
        Persistence of K-ras mutations in plasma after colorectal tumor resection.
        Anticancer Res. 2005; 25: 657-661
        • Morelli M.P.
        • Overman M.J.
        • Dasari A.
        • et al.
        Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
        Ann Oncol. 2015; 26: 731-736
        • Spindler K.L.
        • Pallisgaard N.
        • Vogelius I.
        • Jakobsen A.
        Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
        Clin Cancer Res. 2012; 18: 1177-1185
        • Diaz Jr., L.A.
        • Williams R.T.
        • Wu J.
        • et al.
        The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
        Nature. 2012; 486: 537-540
        • Misale S.
        • Yaeger R.
        • Hobor S.
        • et al.
        Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
        Nature. 2012; 486: 532-536
        • Agostini M.
        • Pucciarelli S.
        • Enzo M.V.
        • et al.
        Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
        Ann Surg Oncol. 2011; 18: 2461-2468
        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-E386
        • Rustgi A.K.
        • El-Serag H.B.
        Esophageal carcinoma.
        N Engl J Med. 2014; 371: 2499-2509
        • Zhai R.
        • Zhao Y.
        • Su L.
        • Cassidy L.
        • Liu G.
        • Christiani D.C.
        Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus.
        Neoplasia. 2012; 14: 29-33
        • Ling Z.Q.
        • Zhao Q.
        • Zhou S.L.
        • Mao W.M.
        MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma.
        Eur J Surg Oncol. 2012; 38: 326-332
        • Kawakami K.
        • Brabender J.
        • Lord R.V.
        • et al.
        Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma.
        J Natl Cancer Inst. 2000; 92: 1805-1811
        • Van Cutsem E.
        • Sagaert X.
        • Topal B.
        • Haustermans K.
        • Prenen H.
        Gastric cancer.
        Lancet. 2016; 388: 2654-2664
        • Kolesnikova E.V.
        • Tamkovich S.N.
        • Bryzgunova O.E.
        • et al.
        Circulating DNA in the blood of gastric cancer patients.
        Ann N Y Acad Sci. 2008; 1137: 226-231
        • Sai S.
        • Ichikawa D.
        • Tomita H.
        • et al.
        Quantification of plasma cell-free DNA in patients with gastric cancer.
        Anticancer Res. 2007; 27: 2747-2751
        • Kim K.
        • Shin D.G.
        • Park M.K.
        • et al.
        Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection.
        Ann Surg Treat Res. 2014; 86: 136-142
        • Ling Z.Q.
        • Lv P.
        • Lu X.X.
        • et al.
        Circulating methylated DNA indicates poor prognosis for gastric cancer.
        PLoS One. 2013; 8: e67195
        • Balgkouranidou I.
        • Karayiannakis A.
        • Matthaios D.
        • et al.
        Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
        Clin Chem Lab Med. 2013; 51: 1505-1510
        • Leung W.K.
        • To K.F.
        • Chu E.S.
        • et al.
        Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer.
        Br J Cancer. 2005; 92: 2190-2194
        • Han J.
        • Lv P.
        • Yu J.L.
        • et al.
        Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer.
        Dig Dis Sci. 2014; 59: 1160-1168
        • Maier J.
        • Lange T.
        • Kerle I.
        • et al.
        Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
        Clin Cancer Res. 2013; 19: 4854-4867
        • Rawnaq T.
        • Schwarzenbach H.
        • Schurr P.G.
        • et al.
        Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence.
        J Surg Res. 2011; 169: 31-35
        • Yoo C.
        • Ryu M.H.
        • Na Y.S.
        • Ryoo B.Y.
        • Park S.R.
        • Kang Y.K.
        Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
        Ann Oncol. 2014; 25: 2272-2277
        • Ryan D.P.
        • Hong T.S.
        • Bardeesy N.
        Pancreatic adenocarcinoma.
        N Engl J Med. 2014; 371: 1039-1049
        • Liggett T.
        • Melnikov A.
        • Yi Q.L.
        • et al.
        Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis.
        Cancer. 2010; 116: 1674-1680
        • Mulcahy H.E.
        • Lyautey J.
        • Lederrey C.
        • et al.
        A prospective study of K-ras mutations in the plasma of pancreatic cancer patients.
        Clin Cancer Res. 1998; 4: 271-275
        • Castells A.
        • Puig P.
        • Mora J.
        • et al.
        K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.
        J Clin Oncol. 1999; 17: 578-584
        • Sorenson G.D.
        Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.
        Clin Cancer Res. 2000; 6: 2129-2137
        • Kinugasa H.
        • Nouso K.
        • Miyahara K.
        • et al.
        Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.
        Cancer. 2015; 121: 2271-2280
        • Sorenson G.D.
        • Pribish D.M.
        • Valone F.H.
        • Memoli V.A.
        • Bzik D.J.
        • Yao S.L.
        Soluble normal and mutated DNA sequences from single-copy genes in human blood.
        Cancer Epidemiol Biomarkers Prev. 1994; 3: 67-71
        • Yi J.M.
        • Guzzetta A.A.
        • Bailey V.J.
        • et al.
        Novel methylation biomarker panel for the early detection of pancreatic cancer.
        Clin Cancer Res. 2013; 19: 6544-6555
        • Melnikov A.A.
        • Scholtens D.
        • Talamonti M.S.
        • Bentrem D.J.
        • Levenson V.V.
        Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
        J Surg Oncol. 2009; 99: 119-122
      1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943
        • Zucman-Rossi J.
        • Villanueva A.
        • Nault J.C.
        • Llovet J.M.
        Genetic landscape and biomarkers of hepatocellular carcinoma.
        Gastroenterology. 2015; 149: 1226-1239.e4
        • Schagdarsurengin U.
        • Wilkens L.
        • Steinemann D.
        • et al.
        Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
        Oncogene. 2003; 22: 1866-1871
        • Chen K.
        • Zhang H.
        • Zhang L.N.
        • et al.
        Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
        World J Gastroenterol. 2013; 19: 3143-3149
        • Tokuhisa Y.
        • Iizuka N.
        • Sakaida I.
        • et al.
        Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma.
        Br J Cancer. 2007; 97: 1399-1403
        • Iizuka N.
        • Sakaida I.
        • Moribe T.
        • et al.
        Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
        Anticancer Res. 2006; 26: 4713-4719
        • Kirk G.D.
        • Lesi O.A.
        • Mendy M.
        • et al.
        249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
        Oncogene. 2005; 24: 5858-5867
        • Lee S.
        • Lee H.J.
        • Kim J.H.
        • Lee H.S.
        • Jang J.J.
        • Kang G.H.
        Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
        Am J Pathol. 2003; 163: 1371-1378
        • Iida M.
        • Iizuka N.
        • Sakaida I.
        • et al.
        Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma.
        Oncol Rep. 2008; 20: 761-765
        • El-Shazly S.F.
        • Eid M.A.
        • El-Sourogy H.A.
        • Attia G.F.
        • Ezzat S.A.
        Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma.
        Int J Biol Markers. 2010; 25: 79-86
        • Montesano R.
        • Hainaut P.
        • Wild C.P.
        Hepatocellular carcinoma: from gene to public health.
        J Natl Cancer Inst. 1997; 89: 1844-1851
        • Kirk G.D.
        • Camus-Randon A.M.
        • Mendy M.
        • et al.
        Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia.
        J Natl Cancer Inst. 2000; 92: 148-153
        • Umoh N.J.
        • Lesi O.A.
        • Mendy M.
        • et al.
        Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia.
        Liver Int. 2011; 31: 215-221
        • Gouas D.A.
        • Villar S.
        • Ortiz-Cuaran S.
        • et al.
        TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.
        Carcinogenesis. 2012; 33: 1219-1224
        • Hosny G.
        • Farahat N.
        • Tayel H.
        • Hainaut P.
        Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
        Cancer Lett. 2008; 264: 201-208
        • Yu J.
        • Ni M.
        • Xu J.
        • et al.
        Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.
        BMC Cancer. 2002; 2: 29
        • Chan K.C.
        • Lai P.B.
        • Mok T.S.
        • et al.
        Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
        Clin Chem. 2008; 54: 1528-1536
        • Iyer P.
        • Zekri A.R.
        • Hung C.W.
        • et al.
        Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients.
        Exp Mol Pathol. 2010; 88: 107-111
        • Han L.Y.
        • Fan Y.C.
        • Mu N.N.
        • et al.
        Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma.
        Int J Med Sci. 2014; 11: 164-171
        • Ren N.
        • Ye Q.H.
        • Qin L.X.
        • Zhang B.H.
        • Liu Y.K.
        • Tang Z.Y.
        Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
        World J Gastroenterol. 2006; 12: 3911-3914
        • Ren N.
        • Qin L.X.
        • Tu H.
        • Liu Y.K.
        • Zhang B.H.
        • Tang Z.Y.
        The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma.
        J Cancer Res Clin Oncol. 2006; 132: 399-407
        • Lo Y.M.
        • Tein M.S.
        • Lau T.K.
        • et al.
        Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis.
        Am J Hum Genet. 1998; 62: 768-775
        • Lee T.H.
        • Montalvo L.
        • Chrebtow V.
        • Busch M.P.
        Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma.
        Transfusion. 2001; 41: 276-282
        • Jung M.
        • Klotzek S.
        • Lewandowski M.
        • Fleischhacker M.
        • Jung K.
        Changes in concentration of DNA in serum and plasma during storage of blood samples.
        Clin Chem. 2003; 49: 1028-1029
        • Thijssen M.A.
        • Swinkels D.W.
        • Ruers T.J.
        • de Kok J.B.
        Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.
        Anticancer Res. 2002; 22: 421-425
        • El Messaoudi S.
        • Rolet F.
        • Mouliere F.
        • Thierry A.R.
        Circulating cell free DNA: preanalytical considerations.
        Clin Chim Acta. 2013; 424: 222-230
        • Sozzi G.
        • Roz L.
        • Conte D.
        • et al.
        Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays.
        J Natl Cancer Inst. 2005; 97: 1848-1850
        • De Mattos-Arruda L.
        • Cortes J.
        • Santarpia L.
        • et al.
        Circulating tumour cells and cell-free DNA as tools for managing breast cancer.
        Nat Rev Clin Oncol. 2013; 10: 377-389
        • Di Gioia S.
        • Bianchi P.
        • Destro A.
        • et al.
        Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.
        BMC Cancer. 2006; 6: 89
        • Terry M.B.
        • Delgado-Cruzata L.
        • Vin-Raviv N.
        • Wu H.C.
        • Santella R.M.
        DNA methylation in white blood cells: association with risk factors in epidemiologic studies.
        Epigenetics. 2011; 6: 828-837